{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"20"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"20"}],"units":"Participants"}],"groups":[{"description":"Participants with a deleterious mutation in one of the following genes: BRCA1, BRCA2, PALB2, RAD51C, or RAD51D.","id":"OG000","title":"Rucaparib Cohort A"},{"description":"Participants with a deleterious mutation in one of the following genes: BARD1, BRIP1, FANCA, NBN, RAD51, or RAD51B.","id":"OG001","title":"Rucaparib Cohort B"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety Population - all enrolled participants who received at least 1 dose of protocol-specified treatment.","reportingStatus":"POSTED","timeFrame":"From first dose of study drug until disease progression (up to approximately 2 years)","title":"Number of Participants Experiencing Treatment-emergent Adverse Events","type":"SECONDARY","unitOfMeasure":"Participants"}